Key Revisions Finalized for Federal IDR Processes Under No Surprises Act
The Departments of Health and Human Services, Labor, and Treasury and the Office of Personnel Management released a final rule May 28 to improve the...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
Stay Compliant with CMS and the New ABN Requirements
The Centers for Medicare & Medicaid Services (CMS) has issued an updated version of the Advance Beneficiary Notice of Noncoverage (ABN).
Prior Authorization Process Reform in Medicare Advantage Gaining Traction in Congress
The Improving Seniors’ Timely Access to Care Act (S.1816/H.R.3514) is gaining significant bipartisan support in both chambers of Congress.